P-004 - DRUG-INDUCED HYPERBILIRUBINEMIA VIA UGT1A1 INHIBITION: LEARNINGS FROM CASE STUDIES AND CONSIDERATIONS FOR DRUG DEVELOPMENT IN ONCOLOGY.

O. Akinjole¹, T. Greway², S. Girgis², Y. Guo³; ¹University of Missouri-Kansas City, Kansas City, MO, USA, ²Janssen Pharmaceuticals, Raritan, NJ, USA, ³Janssen Pharmaceuticals, Spring House, PA, USA.